GRAPH2EM2502 - CME/CMLE - Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Emerging Science and Current Treatment

Course Description

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Emerging Science and Current Treatment

Activity Description:

This case-based activity is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in applying practice-changing updates regarding HER2-low and HER2-ultralow advanced breast cancer. Through three case-based microlearning activities learners will answer questions designed to help them carefully consider the nuances of HER2-low and HER2-ultralow breast cancer diagnosis. This is the second of the three activities and focuses on the emerging science of HER2-low and HER2-ultralow and current treatment for HER2-low and HER2-ultralow patients.

Course topics include:

Emerging science around HER2-low and HER2-ultralow

Current and evolving treatment strategies for patients with HER2-low and HER2-ultralow breast cancer

Target Audience

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.

Faculty/Authors
Mamatha Chivukula, MD
Director of Breast Pathology Services
Mills Peninsula Medical Center, Burlingame, CA

Physician Competencies: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement

Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.

Method of Participation
To complete the activity and receive credit, the participant must attend the program. CME certificates will be provided online. 

Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

Review the Technical Considerations.
Click Go to Content and click the first module of the course.
Complete the Demographic Survey.
Complete the Pre-Test.
Review the Educational Activity.
Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures

Technical Considerations

Release Dates: 3/17/2025
Review Date:
Expiration Date: 3/17/2028

Course Objectives

Upon completion of this activity, you will be able to:

Describe the emerging science and clinical significance of low and ultra-low HER2 expression in breast cancer

Evaluate current and evolving treatment strategies for patients with low and ultra-low HER2 expression

Summary


Availability:	On-Demand


Credit Offered:	0.25 CME/CMLE Credit